Fifth International Conference on Ovarian Cancer: Challenges and opportunities Journal Article
| Authors: | Sood, A. K.; Abu-Rustum, N. R.; Barakat, R. R.; Bodurka, D. C.; Brown, J.; Donato, M. L.; Poynor, E. A.; Wolf, J. K.; Gershenson, D. M. |
| Article Title: | Fifth International Conference on Ovarian Cancer: Challenges and opportunities |
| Abstract: | Objective. This paper provides a summary of the presentations given at the Fifth International Conference on Ovarian Cancer in Houston, Texas on December 1-4, 2004. Methods and Results. The focus of this meeting was to discuss the most current information regarding development, progression, diagnosis, and therapy of ovarian cancer. The presentations at this conference were grouped into 7 sessions, and are summarized in this paper as follows: ovarian cancer biology, novel therapeutic approaches, surgical and pathological controversies, quality of life/biobehavioral aspects of ovarian cancer, screening/prevention approaches, management of uncommon ovarian cancers, and treatment controversies. Conclusion. While many challenges remain in the overall management of ovarian carcinoma, the speakers at this conference reviewed the opportunities available to scientists and clinicians to work collaboratively to make advances. © 2005 Elsevier Inc. All rights reserved. |
| Keywords: | cancer chemotherapy; cancer survival; cancer surgery; survival rate; treatment failure; unclassified drug; clinical trial; drug tolerability; histopathology; review; cancer recurrence; percutaneous endoscopic gastrostomy; cisplatin; cancer combination chemotherapy; drug efficacy; nonhuman; side effect; united states; drug targeting; pathophysiology; paclitaxel; cancer adjuvant therapy; comparative study; postoperative care; cancer staging; nuclear magnetic resonance imaging; positron emission tomography; antineoplastic agent; cancer diagnosis; diagnostic accuracy; laparotomy; preoperative evaluation; genetic analysis; treatment indication; ovarian cancer; ovarian neoplasms; carboplatin; cancer prevention; quality of life; bortezomib; computer assisted tomography; ovary cancer; etoposide; ovariectomy; signal noise ratio; weight reduction; cancer screening; cyclophosphamide; diagnostic approach route; antineoplastic activity; cytotoxicity; vasculotropin inhibitor; cancer therapy; experimental mouse; vinblastine; risk assessment; carcinogenesis; health insurance; survival time; disease severity; medical information; drug mechanism; population risk; echography; granulosa cell tumor; long term care; bleomycin; cancer relapse; platinum derivative; perioperative period; intestine obstruction; ovary teratoma; health care organization; germ cell tumor; drug sensitivity; lung fibrosis; protein mlh1; yolk sac tumor; azacitidine; social psychology; genetic counseling; international cooperation; prodrug; cytostasis; health care management; process development; 6 [4 (4 ethyl 1 piperazinylmethyl)phenyl] 4 (alpha methylbenzylamino) 7h pyrrolo[2,3 d]pyrimidine; international conference; canfosfamide; dysgerminoma; meeting highlights; androblastoma; drug detoxification |
| Journal Title: | Gynecologic Oncology |
| Volume: | 97 |
| Issue: | 3 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2005-06-01 |
| Start Page: | 916 |
| End Page: | 923 |
| Language: | English |
| DOI: | 10.1016/j.ygyno.2005.03.013 |
| PUBMED: | 15907981 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 7" - "Export Date: 24 October 2012" - "CODEN: GYNOA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
629Barakat -
32Poynor -
890Abu-Rustum
Related MSK Work